Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06488313 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Name: A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD — clinical trial record (NCT06488313)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorArcturus Therapeutics, Inc.

Started2024-11-04

View on ClinicalTrials.gov ↗

Record status

This record was last updated March 17, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

Amendment record

Amended 2 times since 2024-06-28; most recent filed 2025-03-13. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2025-03-13

Amendment Study Status v2

2024-07-03

Amendment Study Identification, Study Status v1

2024-06-28

Original filing

Trial Details

NCT Number	NCT06488313
Lead Sponsor	Arcturus Therapeutics, Inc.
Conditions	OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD
Enrollment	9 participants
Start Date	2024-11-04
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-09-01 (estimated)
Updated on ClinicalTrials.gov	2025-03-17